Hello Heart’s flagship product pairs an FDA-cleared blood pressure monitor with an AI-based mobile app that tracks blood pressure, pulse, medications, weight and activity and provides real-time alerts and digital coaching. The company says its app has the highest engagement rate in the category and sustained long-term engagement, and its solution is now available to millions of members. Hello Heart recently doubled the number of employer clients served in the last couple of months, driven by increased employer demand following public health guidance on hypertension and home blood pressure monitoring. Peer-reviewed analysis of over 28,000 Hello Heart users found reduced median systolic blood pressure in over 85% of users who had Stage 2 hypertension at baseline, and greater engagement was associated with lower systolic blood pressure over time. The Validation Institute validated Hello Heart’s ROI methodology and estimated a reduction in total employer medical spend of about $1,865 per participant per year. Looking ahead, Hello Heart plans to deepen its AI engines, enhance lifestyle digital coaching modules, and add whole heart health functionality such as deeper medication tracking, cholesterol tracking, and hyperlipidemia digital coaching. Hello Heart’s flagship product is an AI‑based smartphone solution that helps users track blood pressure, pulse, medications, and activity while delivering personalized, clinically informed feedback and suggestions. The app identifies hypertensive crises or irregular heartbeats and facilitates timely referrals to clinicians to prevent catastrophic cardiac events. The company reports it has tripled its business over the past year and its program is offered by large enterprise customers, including many Fortune 500 employers, as part of benefits programs. Hello Heart is the only digital therapeutic hypertension solution with a peer‑reviewed clinical study on blood pressure outcomes and has been recognized for hypertension management by the American Heart Association. CVS Health added Hello Heart to its Point Solutions Management platform after clinical and security review. In a retrospective peer‑reviewed study led by researchers from UCLA and Harvard Medical School, 70% of users reduced their blood pressure and the average systolic decrease was 22 mmHg, results the company says are over 2x higher than other published peer‑reviewed clinical studies. CEO Maayan Cohen says the company will use the new funding to rapidly scale teams and technology and to build on its leadership position in digital therapeutics for cardiovascular disease. Hello Heart combines an at-home blood-pressure sensing system with an integrated smartphone app that prompts users on behaviors to reduce high blood pressure. The company leverages new remote sensing and monitoring technologies and targets prevention of heart disease through early monitoring and behavior change. Hello Heart has positioned itself to work with corporate insurance programs that are expanding preventative treatment to reduce long-term costs. The company raised $12 million in new financing and said it will use the funds to expand its business. A retrospective study paid for by Hello Heart and conducted by researchers at UCLA and Harvard Medical School found 70% of Hello Heart users reduced their blood pressure by an average of 22 mmHg. Hello Heart collects patient data in a randomized and anonymized fashion and the company states it does not sell data to third parties. Hello Heart offers an iPhone app that automatically pulls lab results and medical data from electronic health records to help users track and understand their health metrics. The app helps patients interpret readings related to diabetes risk, hypertension, and cholesterol, and the company says it is integrated with health records systems used by more than 50 percent of US hospitals and clinics. Users can also manually enter blood pressure readings or sync data from smart blood pressure monitors via Apple’s HealthKit. CEO Maayan Cohen highlights that 50 percent of Americans struggle to understand out-of-range lab results, and the product aims to make that information easy and even fun to track. Hello Heart plans to add support for the Apple Watch once the wearable launches next month. The company is based in Redwood, California.

Total raised

$128M

Funding rounds

4

Latest round

Series D

Latest activity

May 2022